Question · asked by 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE: Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months)

Population
patients with schizophrenia
Intervention
RISPERIDONE DEPOT
Comparison
ARIPIPRAZOLE
Outcome
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months)

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL ARIPIPRAZOLE (very low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE
Adverse events: Movement disorder ‐ any extra pyramidal symptoms · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL ARIPIPRAZOLE (very low certainty).
Risperidone (depot) for schizophrenia (2016) · Cochrane Headline outcomes only
RR 1.19 [0.91, 1.55]2 studies · 729 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Risperidone (depot) for schizophrenia
2016 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.